Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

H. Vallet, S. Riviere, A. Sanna, A. Deroux, G. Moulis, O. Addimanda, C. Salvarani, M. Lambert, P. Bielefeld, P. Seve, J. Sibilia, Jl Pasquali, Jb Fraison, I. Marie, L. Perard, L. Bouillet, F. Cohen, D. Sene, Y. Schoindre, O. LidoveP. Le Hoang, E. Hachulla, O. Fain, X. Mariette, T. Papo, B. Wechsler, B. Bodaghi, M. Resche Rigon, P. Cacoub, D. Saadoun

Research output: Contribution to journalArticlepeer-review


Objective: To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD). Methods: We performed a multicenter study of main characteristics and outcomes of anti-TNF alpha treatments [mainly infliximab (62%), and adalimumab (30%)] in 124 BD patients [48% of men; median age of 33.5 (28-40) years]. Results: Overall response (i.e. complete and partial) rate was 90.4%. Clinical responses were observed in 96.3%, 88%, 70%, 77.8%, 92.3% and 66.7% of patients with severe and/or refractory ocular, mucocutaneous, joint, gastro-intestinal manifestations, central nervous system manifestations and cardiovascular manifestations, respectively. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent. The incidence of BD flares/patient/year was significantly lower during anti-TNF treatment (0.2±0.5 vs 1.7±2.4 before the use of anti-TNF, p

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalJournal of Autoimmunity
Publication statusPublished - Aug 1 2015


  • Anti-TNF
  • Behçet's disease
  • Efficacy
  • Safety
  • Vasculitis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients'. Together they form a unique fingerprint.

Cite this